AMOEBA (EPA:ALMIB) - AMOEBA : Promising results of the Biocontrol-Grapevine application despite a very strong

Transparency directive : regulatory news

29/07/2021 17:45

PRESS RELEASE

Promising results of the Biocontrol-Grapevine application despite a very strong
                                "downy mildew year"

Chassieu (France), July 29th, 2021 - 5:45 p.m. - AMOÉBA (FR0011051598 -
ALMIB), producer of a biological biocide capable of eliminating bacterial risk
in water and human wounds, and of a biocontrol product for plant protection,
still in the development phase, announces the results of the third field trial
campaign against grapevine downy mildew and powdery mildew of its biocontrol
solution, in a very strong mildew year

A difficult meteorological context very favourable to downy mildew.

In France, after heavy frosts in April, May was relatively cold and the few
rains did not cause any contamination.

A rise in temperatures was observed in June until a short period of heat wave.
From 10-15 June, episodes of heavy rain followed one another, causing sudden
and very important contaminations on leaves and bunches in many regions:
Bordeaux, South-West more generally, Champagne, East, as well as Burgundy and
Beaujolais to a lesser extent.

Thus, significant and sometimes unprecedented damage was observed in these
different regions.

Faced with these exceptional disease pressure conditions, even the products
considered to be the most effective against downy mildew were put to the test.
Copper (Bordeaux mixture), at its full rate of 750 g/ha per application,
applied every 7 days, was regularly ineffective, showing only insufficient
protection in many trials, contrary to what was observed in previous years.

Nevertheless, such conditions are favourable for testing products under
development.

Results of the grapevine downy mildew field trials

In 27 field trials in 8 European countries, the following points could be
confirmed by Amoeba:

* Extreme conditions of downy mildew attack are too difficult for 100%
  biocontrol treatment programs : all registered reference biocontrol products
  and Amoéba's experimental products could only provide a small initial
  protection and then were insufficiently effective.
* On the other hand, in all situations where the rains at the end of June were
  a little less sustained and less repeated, and despite significant disease
  pressure, the experimental products of Amoeba confirmed their effectiveness,
  frequently at the level of copper.
* Moreover, the associations between the experimental products of Amoeba and a
  reduced dose of copper (150 g/ha, i.e. 1/5 of the maximum dose), have once
  again ensured sufficient protection, at least equivalent to that of a copper
  program at a practical dose of about 3000 g/ha/year, in many European
  vineyards: South-East of France, Muscadet, Italy (Friuli and Piedmont), North
  Portugal, Spain (Galicia), Hungary, Bulgaria.
* The formulations of Amoéba's experimental products have been improved again
  this year: several have been compared and a SC (suspension concentrate)
  formulation, newly tested during this field trial campaign, proved to be
  superior to the others in 80% of cases.

Trials for future marketing authorization applications require products to be
tested on their own throughout the season to assess their intrinsic efficacy.
This type of protocol, which is not representative of wine-growing practice,
has enabled us to confirm, for the third consecutive year in the field, the
activity of the active substance, but also to verify that in the event of very
high downy mildew pressure, it is advisable to opt for conventional protection
in addition to biocontrol products.

The results of the strategy of combining Amoeba's experimental products with
copper, which allows for a reduction in the amount of copper used per hectare
to around 1,500 g/year, are once again very encouraging in view of the
regulatory review of copper at European level (scheduled for 2026), which could
lead to a reduction in the authorized dose (today 28 kg of copper per hectare
over a period of seven years is authorized, i.e. 4,000 g/ha/year smoothed over
7 years).

"In this difficult year, Amoéba's experimental products confirm their
effectiveness, their potential to reduce chemical fungicides, and their good
complementarity with a reduced dose of copper," says Jean Luc SOUCHE,
Biocontrol Business Developer of Amoéba.

Very promising results on powdery mildew

After an interesting first trial in 2019 (no internal experimentation in 2020),
a few trials were conducted on powdery mildew on grapes in France and Italy.
All the contaminated trials show a very clear effectiveness of Amoéba's
experimental products, reaching 90% effectiveness on bunches in a trial where
the disease intensity is high, i.e. an effectiveness almost equivalent to that
of sulphur under the same conditions.

"These good results, which will be the subject of a large confirmation trials
program in 2022, could support a marketing authorization application against
this disease. Such a versatility of downy mildew and powdery mildew in the same
biocontrol product would be an important competitive advantage," says Jean Luc
SOUCHE, Biocontrol Business Developer of Amoéba.

As announced in April 2021, Amoeba is currently conducting a large-scale cereal
trial campaign and will report the results as soon as efficacy and yield data
are available.

About AMOEBA:
Amoéba's ambition is to become a major player in the treatment of bacterial
risk in the fields of water, healthcare and plant protection. Our biological
solution is an alternative to chemical products widely used today. Amoéba is
currently focusing on the market of industrial cooling towers estimated at
EUR1.7Bn (1) on a global chemical biocide market for water treatment, evaluated
at EUR21Bn (2) and on the biocontrol market for plant protection estimated
globally at EUR1.6Bn (4). In the future, the Company is looking at developing
new applications such as chronic wound care, estimated at EUR 751 million (3)
in the USA. Sales of associated products with healthcare, biocides and crop
protection are subject to the Company being granted local regulatory market
authorizations. The Company is currently in a trial phase for biocidal and
plant protection applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada
and in the United States, Amoéba is quoted on Euronext Growth. The Company is
a member of the BPIfrance Excellence network and is eligible for the PEA-PME
SME equity savings plan setup. More information on www.amoeba-nature.com.

(1) : Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013
(2) : Sources combined by Amoéba from water treaters, Freedonia, Eurostat et
MarketsandMarkets
(3): BCC Research, "Markets for Advanced Wound Management Technologies,"
Wellesley, MA, 2017
(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts: Amoéba
Valérie FILIATRE Directeur Général Adjoint
+33 4 26 69 16 00
v.filiatre@amoeba-nature.com

Calyptus
Relations investisseurs & Presse
Grégory BOSSON / Mathieu CALLEUX
+33 1 53 65 37 90 /91
amoeba@calyptus.net

Disclaimer
This press release contains certain forward-looking statements concerning
AMOEBA which are based on its own assumptions and hypothesis and on information
that are available to us. However, AMOEBA gives no assurance that the estimates
contained in such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the Universal
Registration Document of AMOEBA filed with the French Financial Markets
Authority (Autorité des Marchés Financiers) on April 12, 2021 under number
D21-0289 (a copy of which is available on www.amoeba-nature.com). The
forward-looking statements contained in this press release are also subject to
risks not yet known to AMOEBA or not currently considered material by AMOEBA.
The occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of AMOEBA to be materially
different from such forward-looking statements.

Adresse : 38 Avenue des Frères Montgolfier, 69680 CHASSIEU
Société Anonyme au capital de 341 109,20 EUR
RCS Lyon 523 877 215

Tel: +33 (0)4 26 69 16 00 ? Email: contact@amoeba-nature.com
Linkedin: @amoeba-nature ? Twitter: @AmoebaNature
www.amoeba-nature.com

AMOEBA's latest news

02/05/2024 18:00

AMOEBA (EPA:ALMIB) - AMOEBA : Promising results of the Biocontrol-Grapevine application despite a very strong

Transparency directive : regulatory news

AMOEBA's latest news

Other stories